Contact usLogin

Ferric Carboxymaltose

Uses

Ferric Carboxymaltose is used in the treatment of iron deficiency anemia and anemia associated with chronic kidney disease.

How it Works

How Ferric Carboxymaltose works Ferric Carboxymaltose is an anti-anemic medication that replenishes the iron stores in your body. Iron is essential for the formation of new red blood cells and hemoglobin, the substance that enables these cells to transport oxygen.

Side Effects

Common side effects of Ferric Carboxymaltose include vomiting, nausea, dark-colored stool, headache, dizziness, high blood pressure, and injection site reactions such as pain, swelling, and redness.

Expert Advice

  • Ferric Carboxymaltose is used for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be utilized.
  • Your doctor or nurse will administer it via injection.
  • You will be observed for at least 30 minutes after each injection, as it may cause an allergic reaction.
  • Your blood pressure and blood iron levels will be regularly monitored during treatment with this medication.
  • Inform your doctor if you are taking any iron-containing products orally.
  • Do not consume alcohol while undergoing treatment with this medicine, as it may exacerbate its side effects.
  • It may cause your stools to appear black or dark in color; this is normal and harmless.

Other Combinations

Frequently asked questions

There is limited data on the use of Ferric Carboxymaltose in pregnancy. It is crucial to inform your doctor if you are pregnant or planning to become pregnant. Consult your doctor if pregnancy occurs during treatment, as they will determine whether to continue or discontinue the medication.
Yes, Ferric Carboxymaltose may cause a temporary rise in blood pressure, along with facial flushing, dizziness, and nausea, typically occurring shortly after administration and resolving within 30 minutes.
Typically, two doses are administered 7 days apart. Hemoglobin levels should be assessed at least 4 weeks after the final injection to allow for red blood cell formation. If iron deficiency persists, re-administration may be considered based on individual needs.
Ferric Carboxymaltose vials should be stored at 20°C to 25°C (68°F to 77°F) and must not be frozen. The storage temperature should not exceed 30°C (86°F) or drop below 15°C (59°F).
Ferric Carboxymaltose should only be administered by trained staff capable of managing severe allergic reactions. It can be given as an undiluted injection directly into the vein or via a dialyzer for dialysis patients. Alternatively, it may be diluted with sodium chloride for infusion. Patients must be monitored for at least 30 minutes post-injection, and it should not be administered subcutaneously or intramuscularly.
If leakage occurs, administration must be stopped immediately to prevent skin irritation and potential long-lasting brown discoloration at the site.
;